Stifel analyst Paul Matteis lowered the price target on Biogen (NASDAQ: BIIB) to $304.00 (from $344.00) while maintaining a Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE